Oncology News and Research

RSS
TxCell to deliver two presentations on Col-Treg and Ovasave at ISCT Annual Meeting

TxCell to deliver two presentations on Col-Treg and Ovasave at ISCT Annual Meeting

Inhibitors BGB324 and BGB10C9 show promise in multiple murine models of pancreatic cancer

Inhibitors BGB324 and BGB10C9 show promise in multiple murine models of pancreatic cancer

‘Real-world’ sunitinib findings support trial results

‘Real-world’ sunitinib findings support trial results

Study sheds light on genetic differences between colorectal cancer in older and younger patients

Study sheds light on genetic differences between colorectal cancer in older and younger patients

Eli Lilly to present Phase III PROCLAIM trial results at ASCO Annual Meeting

Eli Lilly to present Phase III PROCLAIM trial results at ASCO Annual Meeting

MIT, UCSD researchers use probiotics to detect cancer in the liver

MIT, UCSD researchers use probiotics to detect cancer in the liver

New EU Clinical Trials Regulation may prove to be challenging for cancer research in Europe

New EU Clinical Trials Regulation may prove to be challenging for cancer research in Europe

Larger studies needed to validate multigene testing for prediction of breast cancer risk

Larger studies needed to validate multigene testing for prediction of breast cancer risk

Array BioPharma presents clinical data of BRAF, MEK and HER2 drugs at 2015 ASCO Annual Meeting

Array BioPharma presents clinical data of BRAF, MEK and HER2 drugs at 2015 ASCO Annual Meeting

DNA analysis reveals how ovarian cancer takes genetic twists and turns to outsmart chemotherapy

DNA analysis reveals how ovarian cancer takes genetic twists and turns to outsmart chemotherapy

RPCI researchers develop individualized post-operative survival calculator for colon cancer patients

RPCI researchers develop individualized post-operative survival calculator for colon cancer patients

Incidence of melanoma on the rise among children and young adults

Incidence of melanoma on the rise among children and young adults

Monoclonal antibody nivolumab improves survival rates of melanoma patients

Monoclonal antibody nivolumab improves survival rates of melanoma patients

MEDI4736 and tremelimumab combination shows acceptable safety, potential efficacy in NSCLC patients

MEDI4736 and tremelimumab combination shows acceptable safety, potential efficacy in NSCLC patients

JAK2 inhibitor ruxolitinib shows promise in treating CMML patients

JAK2 inhibitor ruxolitinib shows promise in treating CMML patients

Green tea components may help prevent prostate cancer development in at-risk men

Green tea components may help prevent prostate cancer development in at-risk men

Study: New cases of cancer rising globally, but death rates falling in many countries

Study: New cases of cancer rising globally, but death rates falling in many countries

Boehringer Ingelheim, University of Michigan partner to discover new medicines for diabetic nephropathy

Boehringer Ingelheim, University of Michigan partner to discover new medicines for diabetic nephropathy

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

PDS Biotechnology announces positive results from PDS0101 Phase I trial in pre-cervical cancer patients

PDS Biotechnology announces positive results from PDS0101 Phase I trial in pre-cervical cancer patients

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.